Search research articles
Contact Us
Filters
Showing results (141-150 of 157) with videos related to
Page
of 16
Sort By:
Cell Death & Disease
|
October 6, 2021
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance
Yi-Ying Wu, Hsing-Fan Lai, Tzu-Chuan Huang, et al.
Scientific Reports
|
August 21, 2024
Immune killer cells treatment for previously treated stage IV NSCLC patients
Yen-Han Tseng, Ching-Liang Ho, Chih-Feng Chian, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
May 6, 2026
Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort"
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
May 22, 2026
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX"
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)
Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
JCO Global Oncology
|
September 30, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521
Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, et al.
The Lancet. Oncology
|
March 29, 2012
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, et al.
Medicine
|
May 5, 2021
Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis
Po-Huang Chen, Yi-Ying Wu, Cho-Hao Lee, et al.
Cancer
|
August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study
Hui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 157) with videos related to
Sort By:
Page
of 16
Cell Death & Disease
|
October 6, 2021
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance
Yi-Ying Wu, Hsing-Fan Lai, Tzu-Chuan Huang, et al.
Scientific Reports
|
August 21, 2024
Immune killer cells treatment for previously treated stage IV NSCLC patients
Yen-Han Tseng, Ching-Liang Ho, Chih-Feng Chian, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
May 6, 2026
Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort"
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
May 22, 2026
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX"
I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)
Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
JCO Global Oncology
|
September 30, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521
Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, et al.
The Lancet. Oncology
|
March 29, 2012
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, et al.
Medicine
|
May 5, 2021
Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis
Po-Huang Chen, Yi-Ying Wu, Cho-Hao Lee, et al.
Cancer
|
August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study
Hui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Page
of 16